Baker BROS. Advisors LP Has $719,000 Stock Holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Baker BROS. Advisors LP reduced its holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 96.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 83,055 shares of the company’s stock after selling 1,993,345 shares during the quarter. Baker BROS. Advisors LP’s holdings in Aligos Therapeutics were worth $719,000 as of its most recent SEC filing.

Separately, Armistice Capital LLC grew its stake in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Price Performance

Shares of ALGS stock opened at $25.51 on Monday. The stock has a market capitalization of $91.53 million, a PE ratio of -1.92 and a beta of 2.11. The business’s 50 day simple moving average is $11.83 and its 200 day simple moving average is $12.61. Aligos Therapeutics, Inc. has a one year low of $6.76 and a one year high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The firm had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. During the same period in the prior year, the company posted ($10.25) earnings per share. As a group, research analysts expect that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).